Quoin Pharmaceuticals (QNRX) awards 318,750 ADS options to COO

Rhea-AI Filing Summary

Quoin Pharmaceuticals reported an equity award to its Chief Operating Officer and director Denise P. Carter. On February 4, 2026, she received a share option covering 318,750 American Depositary Shares (ADSs) with an exercise price of $7.37 per ADS, expiring on February 4, 2036.

Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. The option vests in four annual installments, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, she beneficially owns 318,750 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Carter Denise P.

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	318,750	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 318,750 shares (Direct)

Footnotes (1)

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carter Denise P.

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$7.37(1)	02/04/2026		A		318,750(1)		(2)	02/04/2036	ADS	318,750(1)	$0	318,750(1)	D

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

	/s/ Denise Carter	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Quoin Pharmaceuticals (QNRX) report for Denise Carter?

Quoin Pharmaceuticals reported that Chief Operating Officer and director Denise P. Carter received a share option for 318,750 ADSs on February 4, 2026. The option has an exercise price of $7.37 per ADS and represents a new equity award, not a sale of shares.

What are the key terms of Denise Carter’s Quoin (QNRX) stock option grant?

Denise Carter received a share option covering 318,750 ADSs at an exercise price of $7.37 per ADS, granted February 4, 2026. The option expires February 4, 2036 and was reported as directly owned derivative securities following the transaction.

How does the Quoin (QNRX) ADS option translate into ordinary shares?

The filing states that each American Depositary Share (ADS) of Quoin Pharmaceuticals represents thirty-five ordinary shares. The 318,750 ADSs underlying the option are therefore based on this 35-to-1 ratio between ADSs and the company’s ordinary shares.

What is the vesting schedule for Denise Carter’s Quoin (QNRX) option?

The share option vests over four annual installments. Twenty percent vests on each of February 4, 2027, 2028, and 2029, and the remaining forty percent vests on February 4, 2030, according to the vesting terms disclosed in the filing’s footnotes.

When does Denise Carter’s Quoin Pharmaceuticals (QNRX) option expire?

The option granted to Denise Carter has an expiration date of February 4, 2036. It becomes exercisable over time according to the annual vesting schedule from 2027 through 2030, but after the expiration date, it can no longer be exercised for ADSs.

What role does Denise Carter hold at Quoin Pharmaceuticals (QNRX) in this Form 4?

Denise P. Carter is identified as both a director and an officer of Quoin Pharmaceuticals, serving as Chief Operating Officer. The Form 4 indicates she is not a ten percent owner, and the reported derivative securities are held under direct ownership in her name.